Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZW171 in mesothelin-expressing cancers
NCT06523803Phase 1Terminated
- Sponsor
- Zymeworks Inc.
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of ZW171 in ovarian cancer, non-small cell lung cancer (NSCLC) and malignant neoplasm, sponsored by Zymeworks Inc. Primary endpoints: Dose-Limiting Toxicities at 3 weeks, Adverse Events at 2 years and 4 more. Started Sep 2024; status: terminated.
02
Drugs
ZW171
03
Conditions
ovarian cancernon-small cell lung cancer (NSCLC)malignant neoplasm
Beyond the preview
Go deeper on NCT06523803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523803.